ramucirumab相关论文
目的：通过阅读近年来国内、外胃癌靶向治疗相关的临床试验的研究，综述胃癌靶向治疗的现状和未来的发展方向。方法：在pubmed或ISI数据......
会议
美国FDA于2014年4月21日批准Cyramza(ramucirumab)用于治疗晚期胃癌或食管胃交界腺癌(gastroesophageal junction adenocarcinoma)......
Newer active drugs have been recently added to thepharmacological armamentarium for the treatment ofmetastatic colorecta......
主要的肝癌症是死亡的最普通的原因之一。为 90% 主要的肝癌症的 Hepatocellular 癌(HCC ) 报道。为有 unresectable 或变形 HCC ......
Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients
Objective: We aimed to investigate the prognostic value of neutrophil-to-lymphocyte ratio(NLR) and myeloidderived suppre......
BACKGROUND Bronchobiliary fistula(BBF)is a rare disease characterized by an abnormal connection between the biliary syst......
Colorectal cancer(CRC) is a significant cause of cancer-related morbidity and mortality all over the world.Improvements ......
Ramucirumab是礼来公司研发的重组全人IgG1单克隆抗体。本品可以特异性结合人血管内皮生长因子受体2(VEGFR2)的胞外结构域,阻止VEG......
美国FDA于2014年12月12日采用优先审批程序（priority review program）批准Cyramza（ramucirumab）增加新的适用症,即用于治疗转移性非小......
